IREN (IREN) has been added to the Russell 1000 Index as the Russell U.S. Indexes shift from an annual to a semi-annual ...

View Relmada Therapeutics Inc RLMD stock quote prices, financial information, real-time forecasts, and company news from CNN.

Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today ...

NDV-01 Phase 2 NMIBC results, Phase 3 mid-2026 outlook, competition, and $160m financing—read the full analysis.

Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data ...

Relmada Therapeutics Inc. (NASDAQ:RLMD) is one of the best growth stocks under $30 to buy now. On May 12, Relmada Therapeutics reported Q1 2026 results, highlighted by positive 12-month Phase 2 data ...

Dr. Quirk brings more than 20 years of neuroscience drug discovery and development experience to lead Relmada’s sepranolone program, building on ...

Relmada Therapeutics reported a net loss of $0.22 per share, slightly missing expectations. The company strengthened its cash position significantly, with a balance of $234 million. Research and ...

Good afternoon, and welcome to Relmada Therapeutics First Quarter Earnings Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded and will be available for ...

Relmada’s Q1 2026 EPS was slightly below expectations, missing by $0.01. The company reported a substantial cash position, ensuring operations through 2029. R&D expenses decreased significantly, ...